According to the inclusion criteria, 164 patients with HER2-positive breast cancer who received neoadjuvant therapy in the Department of Breast Surgery of the First Affiliated Hospital of Zhengzhou University from July 2018 to July 2022 were collected. Here, ERBB2 is linked to breast carcinoma.